BRPI0513857A - inibidores de hsp90 - Google Patents

inibidores de hsp90

Info

Publication number
BRPI0513857A
BRPI0513857A BRPI0513857-4A BRPI0513857A BRPI0513857A BR PI0513857 A BRPI0513857 A BR PI0513857A BR PI0513857 A BRPI0513857 A BR PI0513857A BR PI0513857 A BRPI0513857 A BR PI0513857A
Authority
BR
Brazil
Prior art keywords
compounds
benzoimidazolone
hsp90 inhibitors
treatment
new
Prior art date
Application number
BRPI0513857-4A
Other languages
English (en)
Inventor
Patrick Chene
Andreas Floersheimer
Pascal Furet
Joseph Schoepfer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0513857A publication Critical patent/BRPI0513857A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

INIBIDORES DE HSP9O. A presente invenção refere-se ao uso de compostos de benzoimidazolona e sais dos compostos no tratamento de doenças proliferativas e para a produção de preparações farmacêuticas para o tratamento dessas doenças, a preparações farmacêuticas que compreendem compostos de benzoimidazolona, a novos compostos de benzoimidazolona, e a um processo para a preparação dos novos compostos de benzoimidazolona.
BRPI0513857-4A 2004-07-27 2005-07-26 inibidores de hsp90 BRPI0513857A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59133004P 2004-07-27 2004-07-27
PCT/EP2005/008118 WO2006010594A1 (en) 2004-07-27 2005-07-26 Inhibitors of hsp90

Publications (1)

Publication Number Publication Date
BRPI0513857A true BRPI0513857A (pt) 2008-05-20

Family

ID=35058768

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513857-4A BRPI0513857A (pt) 2004-07-27 2005-07-26 inibidores de hsp90

Country Status (14)

Country Link
US (1) US20090069341A1 (pt)
EP (1) EP1776110A1 (pt)
JP (1) JP2008508217A (pt)
KR (1) KR20070045290A (pt)
CN (1) CN101027054A (pt)
AR (1) AR050084A1 (pt)
AU (1) AU2005266493B2 (pt)
BR (1) BRPI0513857A (pt)
CA (1) CA2574139A1 (pt)
MX (1) MX2007001131A (pt)
PE (1) PE20060572A1 (pt)
RU (1) RU2007106933A (pt)
TW (1) TW200612922A (pt)
WO (1) WO2006010594A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1704856A4 (en) * 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
AU2006236557A1 (en) * 2005-04-14 2006-10-26 Novartis Vaccines And Diagnostics Inc. 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases
JP2009504673A (ja) * 2005-08-11 2009-02-05 ノバルティス アクチエンゲゼルシャフト ピリミジルアミノベンズアミド化合物であるタンパク質キナーゼ阻害剤および１７−ａａｇのようなｈｓｐ９０阻害剤を含む組合せ
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
WO2007092496A2 (en) * 2006-02-07 2007-08-16 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2008024963A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Benzene, pyridine, and pyridazine derivatives
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
MX2009010296A (es) * 2007-04-18 2009-12-14 Kissei Pharmaceutical Derivado de anillo fusionado nitrogenado, composicion farmaceutica que lo contiene, y uso del mismo para propositos medicos.
CA2700893A1 (en) 2007-10-12 2009-04-16 Arqule, Inc. Substituted tetrazole compounds and uses thereof
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN102786512A (zh) 2012-05-31 2012-11-21 中国人民解放军军事医学科学院毒物药物研究所 N-芳基不饱和稠环叔胺类化合物及其制备方法和抗肿瘤应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239540A (en) * 1990-09-24 1993-11-25 Neurosearch As 1-phenyl benzimidazole derivatives and medicaments
US5621007A (en) * 1993-11-03 1997-04-15 Bristol-Myers Squibb Company Method for regulation of transmembrane chloride conductance
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
WO2005025511A2 (en) * 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier

Also Published As

Publication number Publication date
WO2006010594A1 (en) 2006-02-02
CA2574139A1 (en) 2006-02-02
JP2008508217A (ja) 2008-03-21
AU2005266493B2 (en) 2009-09-10
TW200612922A (en) 2006-05-01
EP1776110A1 (en) 2007-04-25
US20090069341A1 (en) 2009-03-12
MX2007001131A (es) 2007-03-15
AU2005266493A1 (en) 2006-02-02
KR20070045290A (ko) 2007-05-02
RU2007106933A (ru) 2008-09-10
AR050084A1 (es) 2006-09-27
PE20060572A1 (es) 2006-06-27
CN101027054A (zh) 2007-08-29

Similar Documents

Publication Publication Date Title
BRPI0513857A (pt) inibidores de hsp90
BRPI0513819A (pt) inibidores de hsp90
BRPI0509655A (pt) uso de derivados de 9h-purina-2,6-diamina no tratamento de doenças proliferativas e novos derivados de 9h-purina-2,6-diamina
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
BRPI0512237A (pt) cis-imidazolinas
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
BRPI0718587A2 (pt) Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
BRPI0515218A (pt) composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto
BRPI0708071A8 (pt) Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
CL2008000065A1 (es) Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
BRPI0806365B8 (pt) composto, uso do composto, composição farmacêutica e uso da composição farmacêutica
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0607330A2 (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar inflamação ou prevenir apoptose em um indivìduo, e, uso do composto
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.